HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer

BASF SEEKS FDA AUTHORIZATION TO MARKET PEG-25 PABA

This article was originally published in The Rose Sheet

  • News
  • The Rose Sheet

Executive Summary

BASF SEEKS FDA AUTHORIZATION TO MARKET PEG-25 PABA pending the completion of the OTC sunscreen monograph review process. In a Feb. 4 letter, the company's attorney, Kathleen Sanzo from the Washington, D.C. law firm Morgan, Lewis & Bockius requested that FDA "state it is appropriate to include PEG-25 PABA in the OTC monograph review process and that...BASF and any similarly situated manufacturers are authorized to market their products pending completion by FDA of the OTC monograph review process for sunscreens."

Table

View full table

Topics

Tags:
Consumer
Latest Headlines

Unilever Adjusts Sustainable Plastic Goals As Industry Aspirations Meet Systemic Realities

First Generic Of B+L’s OTC Switch Lumify Approved For Dr. Reddy’s Amid Patent Infringement Battle

‘Cowboy Companies’ To Be Named, Shamed And Fined Under EU Supply Chain Directive

Beauty Firms Should Draft AI Use Policies, Even If They Don’t Plan To Use AI – Attorney

See All
UsernamePublicRestriction

Register

RS000135

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By